Eldridge Investment Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Eldridge Investment Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-25,147	Closed	-$2.25M	–	152
2023 Q4	$2.25M	Sell	25,147 -1,765	-7%	-$131K	0.59%	40
2023 Q3	$1.97M	Sell	26,912 -53	-0.2%	-$4.23K	0.65%	31
2023 Q2	$2.24M	Sell	26,965 -2,396	-8%	-$200K	0.73%	32
2023 Q1	$2.24M	Sell	29,361 -523	-2%	-$43.4K	0.78%	30
2022 Q4	$2.48M	Buy	29,884 +1,339	+5%	+$108K	0.87%	27
2022 Q3	$2.26M	Sell	28,545 -26,104	-48%	-$2.2M	0.88%	25
2022 Q2	$4.06M	Buy	+54,649	New	+$4.1M	1.53%	18

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Eldridge Investment Advisors's XBI Position: Q1 2024 in Review

Eldridge Investment Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2024, closing a stake of 25,147 shares — an estimated $2.25M sold.

Eldridge Investment Advisors first reported a position in XBI in Q2 2022 and held it in 7 quarters. The position peaked at $4.06M in Q2 2022. 780 funds tracked by Wall St. Rank hold XBI as of Q1 2024.

Eldridge Investment Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2024 after selling out during the quarter.
Eldridge Investment Advisors sold 25,147 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $2.25M.
Eldridge Investment Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 7 quarters.
Eldridge Investment Advisors's State Street SPDR S&P Biotech ETF position peaked at $4.06M in Q2 2022.
780 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.

Based on Eldridge Investment Advisors's 13F filing for Q1 2024, filed 10 May 2024.